Follow
Samvel B. Gasparyan
Samvel B. Gasparyan
Statistician, AstraZeneca
Verified email at astrazeneca.com - Homepage
Title
Cited by
Cited by
Year
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
MN Kosiborod, R Esterline, RHM Furtado, J Oscarsson, SB Gasparyan, ...
The lancet Diabetes & endocrinology 9 (9), 586-594, 2021
1962021
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
PS Jhund, T Kondo, JH Butt, KF Docherty, BL Claggett, AS Desai, ...
Nature medicine 28 (9), 1956-1964, 2022
1852022
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the …
M Kosiborod, O Berwanger, GG Koch, F Martinez, O Mukhtar, S Verma, ...
Diabetes, Obesity and Metabolism 23 (4), 886-896, 2021
592021
Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF
PS Jhund, P Ponikowski, KF Docherty, SB Gasparyan, M Böhm, ...
Circulation 143 (20), 1962-1972, 2021
482021
Adjusted win ratio with stratification: calculation methods and interpretation
SB Gasparyan, F Folkvaljon, O Bengtsson, J Buenconsejo, GG Koch
Statistical Methods in Medical Research 30 (2), 580-611, 2021
362021
Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials
SB Gasparyan, EK Kowalewski, F Folkvaljon, O Bengtsson, ...
Journal of Biopharmaceutical Statistics 31 (6), 765-787, 2021
192021
Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: an analysis of the DARE-19 randomized controlled trial
HJL Heerspink, RHM Furtado, O Berwanger, GG Koch, F Martinez, ...
Clinical Journal of the American Society of Nephrology 17 (5), 643-654, 2022
152022
Design and analysis of studies based on hierarchical composite endpoints: insights from the DARE-19 trial
SB Gasparyan, J Buenconsejo, EK Kowalewski, J Oscarsson, ...
Therapeutic Innovation & Regulatory Science 56 (5), 785-794, 2022
122022
The maraca plot: a novel visualization of hierarchical composite endpoints
M Karpefors, D Lindholm, SB Gasparyan
Clinical Trials 20 (1), 84-88, 2023
92023
Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER …
PS Jhund, BL Claggett, A Talebi, JH Butt, SB Gasparyan, LJ Wei, ...
JAMA cardiology 8 (6), 554-563, 2023
82023
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression
HL Heerspink, N Jongs, P Schloemer, DJ Little, M Brinker, C Tasto, ...
Journal of the American Society of Nephrology, 10.1681, 2023
52023
Comments on “Sample size formula for a win ratio endpoint” by RX Yu and J. Ganju
SB Gasparyan, EK Kowalewski, GG Koch
Statistics in Medicine 41 (14), 2688-2690, 2022
52022
Second order asymptotical efficiency for a Poisson process
SB Gasparyan
Journal of Contemporary Mathematical Analysis 50, 98-106, 2015
52015
hce: Design and Analysis of Hierarchical Composite Endpoints
SB Gasparyan
R package version>= 0.5. 0, 2022
42022
On approximation of the BSDE with unknown volatility in forward equation
S Gasparyan, Y Kutoyants
Armenian Journal of Mathematics 7 (1), 59-79, 2015
42015
Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review
DJ Little, SB Gasparyan, P Schloemer, N Jongs, M Brinker, M Karpefors, ...
Journal of the American Society of Nephrology 34 (12), 1928-1935, 2023
32023
Basic Data Structure for Hierarchical Composite Endpoints: An Application to Kidney Disease Trials
SB Gasparyan, N Major, C Bäckberg, S Ravikiran, P Wani, M Karpefors, ...
Journal of the Society for Clinical Data Management, 2024
22024
Hierarchical Composite Endpoints in COVID-19: The DARE-19 Trial
SB Gasparyan, EK Kowalewski, J Buenconsejo, GG Koch
Case Studies in Innovative Clinical Trials, 95-148, 2023
22023
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials
T Kondo, SB Gasparyan, PS Jhund, O Bengtsson, BL Claggett, ...
NEJM evidence 2 (11), EVIDoa2300042, 2023
12023
An example of one-step MLE-process in volatility estimation problem
SB Gasparyan, YA Kutoyants
Հայաստանի ԳԱԱ Տեղեկագիր. Մաթեմատիկա 50 (3), 71-76, 2015
12015
The system can't perform the operation now. Try again later.
Articles 1–20